The relationship between circulating 25-hydroxyvitamin D and survival in newly diagnosed advanced non-small-cell lung cancer

Pankaj G. Vashi, Persis Edwin, Brenten Popiel and Digant Gupta

Abstract

Background: Serum 25-hydroxyvitamin D [25(OH)D], the major circulating form of vitamin D used for evaluating the vitamin D status of patients, has been associated with survival in a variety of cancers with conflicting evidence. We aimed to investigate this association in newly diagnosed advanced non-small-cell lung cancer (NSCLC) patients.

Methods: This was a consecutive cohort of 359 newly diagnosed stages III-IV NSCLC patients who underwent a baseline serum 25(OH)D evaluation prior to receiving any treatment at our institution between January 2008 and December 2010. We used the vitamin D categories of “deficient (<20 ng/ml)” and “not deficient (≥20 ng/ml)”. Cox regression was used to evaluate the prognostic significance of serum 25(OH)D after adjusting for relevant confounders.

Results: Mean age at diagnosis was 57.4 years. Of the 359 patients, 151 (42.1 %) were deficient in vitamin D at the time of diagnosis. The median survival in deficient and not deficient cohorts was 11.7 and 12.8 months respectively (p = 0.06). Season of diagnosis, performance status, smoking status and hospital location significantly predicted vitamin D status. On univariate Cox analysis, gender, stage of disease, hospital location, histologic subtype, subjective global assessment (SGA), performance status, smoking status, body mass index and serum albumin were significantly associated with survival (p <0.05 for all). On multivariate Cox analysis, six variables demonstrated statistically significant associations with survival: stage of disease, hospital location, histologic subtype, SGA, smoking status and serum albumin (p <0.05 for all). Serum vitamin D, which was borderline significant in univariate analysis, lost its significance in multivariate analysis.

Conclusions: We found season of diagnosis, performance status and smoking history to be predictive of vitamin D status. Consistent with previously published research in advanced NSCLC, we did not find any significant association between pre-treatment serum 25(OH)D and survival in our patients.

Keywords: Serum 25-hydroxyvitamin D, Lung cancer, Survival

Background

Vitamin D produced in the skin upon sun exposure or ingested from the diet is converted in the liver to 25-hydroxyvitamin D [25(OH)D], the major circulating form of vitamin D used for evaluating the vitamin D status of patients [1, 2]. 25(OH)D is hydroxylated in the kidneys to form the biologically active metabolite 1,25-dihydroxyvitamin D [1,25(OH)2D] [3, 4]. Though 25(OH)D is not the active form of vitamin D, it is known to be the best indicator of vitamin D status as it accurately reflects vitamin D intake from all sources and has a half-life of two to three weeks compared to only four hours for the active form (1,25(OH)2D) [5].

Emerging evidence in the literature suggests an association between serum 25(OH)D and survival in several types of cancer, however, the evidence is not conclusive with regard to the direction and strength of association. While several studies have demonstrated a positive association between serum vitamin D and survival in multiple cancer types including gastric [6], colorectal [7–11], breast [12, 13] and prostate [14],
other studies have demonstrated a lack of such an association [15–17]. Some studies have combined newly diagnosed and previously treated patients in the same analysis [14], while others have found the vitamin D-survival association to become attenuated after adjusting for important confounders [15]. Collectively, these studies indicate that using a homogeneous patient population and adjustment of important confounders are important aspects of study design and data analysis respectively that should be taken into account.

Specific to non-small cell lung cancer (NSCLC), there have been 7 published studies evaluating the relationship between serum 25(OH)D and survival with 3 of them demonstrating positive association, 3 null association and 1 negative association. A study by Zhou et al. conducted in 447 patients with early-stage NSCLC, found higher levels of vitamin D to be associated with improved survival particularly among stage IB-IIIB patients [18]. A Norwegian study of 210 lung cancer patients that collected serum samples shortly after diagnosis, observed that higher serum 25(OH)D was associated with a statistically significant longer survival time [19]. A study conducted in 16,693 men and women participating in the Third National Health and Nutrition Examination Survey found serum 25(OH)D concentrations to be inversely associated with lung cancer mortality in nonsmokers; this association was diminished among those with excess circulating vitamin A [20]. Heist et al. conducted a study in 294 patients with stage III-IV NSCLC and found no difference in survival by circulating vitamin D level quartiles [21]. A prospective study by Turner et al. conducted in a relatively homogeneous group of 148 surgically treated lung cancer patients, found that pre-surgical levels of serum 25(OH)D were not associated with either overall or lung-cancer specific mortality, although the study did report a protective effect of higher vitamin D binding protein on lung-cancer specific mortality [22]. The most recent findings on the lack of a significant relationship between serum vitamin D and survival comes from Anic et al. who investigated 500 male lung cancer cases (staged I–IV) in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Comparing highest to lowest quartiles, there was no statistically significant association between serum 25(OH)D and lung cancer survival [23]. Finally, a Chinese study of 87 NSCLC cases reported a negative association such that higher serum 25(OH)D at diagnosis was associated with a shorter survival time [24].

Given this variability in findings on the relationship between serum vitamin D and survival in NSCLC, additional studies with large sample sizes are needed to better understand the direction and strength of this association. We investigated this association in a large homogenous group of newly diagnosed advanced NSCLC patients treated at a national network of oncology hospitals.

Methods

Study population

A consecutive series of 359 newly diagnosed stages III–IV NSCLC patients treated at three Cancer Treatment Centers of America® (CTCA) hospitals (located in Zion, IL, Philadelphia, PA, and Tulsa, OK) between January 2008 and December 2010 was evaluated. We included a consecutive case series of patients to minimize the probability of selection bias. The present study was conducted according to the guidelines laid down in the Declaration of Helsinki and was approved by the Midwestern Regional Medical Center Institutional Review Board (IRB) at Cancer Treatment Centers of America®. The IRB waived the need for informed consent because there was no direct patient contact in this study. This study involved collection of existing data from patient records in such a manner that subjects could not be identified, directly or through identifiers linked to the subjects.

Vitamin D measurement

Serum samples were collected within 30 days of first visit at our hospital, and prior to initiation of anticancer therapy. Serum was collected at the laboratory, packed in coolpacks and sent to the Laboratory Corporation of America (Raleigh, NC) where a chemiluminescence immune assay (CLIA, DiaSorin Liaison assay) was used to measure 25(OH)D. Serum samples were incubated with antivitamin-D coated microparticles and isoluminol derivative-conjugated 25(OH)D before measurement of chemiluminescent signals. Analysis was completed within 48 h of collection. The DiaSorin Liaison 25(OH)D assay has been clinically validated to be comparable in accuracy and precision to the radioimmunoassay (RIA). This method uses the same particles used in the DiaSorin RIA technique. Studies have found this to be a rapid, accurate, and precise tool for the measurement of serum 25(OH)D [25, 26].

Statistical analysis

Serum 25(OH)D was the primary independent variable of interest. We used the categories “deficient (<20 ng/ml)”, and “not deficient (> = 20 ng/ml)” in accordance with previously published research in this area [12, 14]. A comparison of clinical and demographic characteristics was made between the two vitamin D categories using a two-sample t-test, a Mann Whitney test or a chi-square test depending upon the underlying distribution of the variables.

The primary endpoint was patient survival and was defined as the time interval between the date of first serum vitamin D assessment and the date of death from any cause or the date of last contact/last known to be alive. Patients were followed prospectively until December 2014. The Kaplan-Meier method was used to calculate
survival. The log rank test statistic was used to evaluate the equality of survival distributions across the 2 serum 25(OH)D groups. Clinical, demographic and serum 25(OH)D variables were evaluated using univariate Cox proportional hazards models to determine which parameters showed individual prognostic value for survival. Multivariate Cox proportional hazards models were then performed to evaluate the independent prognostic significance of all variables that were evaluated in univariate analysis. We adjusted for the following variables in the multivariate analysis: age, gender, CTCA hospital, stage of disease, Eastern Cooperative Oncology Group (ECOG) performance status, body mass index (BMI), season of diagnosis, serum albumin, smoking status, histologic subtype, and nutritional status as measured using Subjective Global Assessment (SGA). Season of diagnosis was defined as winter: December-February; spring: March-May; summer: June-August, or fall: September-November. The effect of serum 25(OH)D and other variables on patient survival was expressed as hazard ratios (HRs) with 95 % confidence intervals (CIs).

Cox regression with time-invariant covariates assumes that the ratio of hazards for any two groups remains constant in proportion over time. We checked this proportional hazards (PH) assumption using a combination of graphical and statistical testing procedures. First, we examined log-minus-log plots for categorical predictors. As a second approach, we ran an extended Cox model with time-dependent covariates for continuous predictors. Finally, a goodness-of-fit testing approach based on Schoenfeld residuals was used to evaluate the PH assumption.

Finally, to assess the possible influence of sample bias on the results, as well as to investigate the stability of the model coefficients, we performed a bias-corrected and accelerated (BCa) bootstrap resampling procedure. We generated 1000 samples, each the same size as the original data set, by random selection with replacement. Cox regression was then run separately on these 1000 samples to obtain robust estimates of the standard errors of coefficients, and hence the p values and 95 % BCa CIs of the model coefficients [27].

No formal sample size calculations were conducted for this analysis. All reported P values are from two-sided tests. All statistical analyses utilized SPSS version 20.0 (International Business Machines, Armonk, New York, USA).

**Results**

**Patient characteristics**

Table 1 displays the baseline characteristics of our patients. The median follow-up was 10.8 months. At the time of this analysis, 293 (81.6 %) patients had expired while 66 (18.4 %) were considered censored. 163 (45.4 %) patients were taking vitamin D supplements at the time of diagnosis. 332 (92.5 %) patients received chemotherapy, 191 (53.2 %) received radiation therapy and 24 (6.7 %) received surgery at our institution. A total of 172 (47.9 %) patients received both chemotherapy and radiation therapy at our institution.

**Predictors of vitamin D status**

Table 1 also describes the patient characteristics stratified by the 2 categories of serum vitamin D (deficient and not deficient). Season of diagnosis, ECOG performance status, smoking status and CTCA hospital were the four variables that demonstrated statistical significance (p<0.05). Patients who presented to us in the summer and fall months were less likely to be deficient in vitamin D compared to those who presented in winter and spring. The mean (standard deviation [sd]) serum vitamin D levels were 24.7 (11.8), 31.2 (20.8), 22.3 (10.4) and 23.5 (14.1) nanograms per milliliter (ng/ml) for summer, fall, winter and spring months respectively. Patients with ECOG performance scores of 0–1 were less likely to be deficient in vitamin D compared to those with scores 2–4. Current smoking status was associated with a greater prevalence of vitamin D deficiency compared to past or no smoking history. Finally, patients diagnosed at our Philadelphia hospital had a lower prevalence of vitamin D deficiency compared to patients diagnosed at Zion and Tulsa hospitals. In addition, patients with vitamin D deficiency had lower serum albumin levels compared to patients with non-deficient serum vitamin D levels, the finding being borderline significant (p = 0.06). Similarly, well-nourished patients had a lower prevalence of vitamin D deficiency compared to malnourished patients, the finding being borderline significant (p = 0.07).

**Median survival**

Table 2 shows the median survival times as a function of various clinical and demographic variables. There was no statistically significant difference in the Kaplan-Meier median survival times across the 2 categories of serum vitamin D, as displayed in Fig. 1. Gender, stage of disease, CTCA hospital, histologic subtype, SGA, ECOG performance status and smoking status were significantly associated with survival. Females, patients with stage III disease, well-nourished patients, patients with ECOG score 0–1 and patients with no smoking history had a significantly greater median survival compared to males, patients with stage IV disease, patients with ECOG score 2–4, and smoking history respectively. Patients with adenocarcinoma and squamous cell carcinoma had a significantly greater median survival compared to those with cancers in the “others” category. Finally, patients treated at our Philadelphia hospital had a significantly greater median survival compared to those treated at Zion and Tulsa hospitals.
To further understand the differences in survival across the 3 hospitals, we evaluated the distribution of baseline clinical and demographic characteristics stratified by the hospital (detailed results not shown in the interest of space). The Philadelphia cohort (66%) had a significantly greater proportion of females compared to the Zion (47.6%) and Tulsa (42.5%) cohorts; \( p = 0.04 \).

### Table 1: Patient characteristics for the overall population as well as stratified by 2 serum vitamin D categories

| Categorical variables | Overall population \((n = 359)\) | Deficient: \(<20 \text{ ng/ml} (n = 151)\) | Not deficient: \(\geq 20 \text{ ng/ml} (n = 208)\) | \(P\)-value |
|-----------------------|----------------------------------|---------------------------------|-------------------------------|-------------|
| Gender                |                                  |                                 |                               | 0.85        |
| Male                  | 181                              | 77 (42.5)                       | 104 (57.5)                    |             |
| Female                | 178                              | 74 (41.6)                       | 104 (58.4)                    |             |
| Stage                 |                                  |                                 |                               | 0.90        |
| III                   | 94                               | 39 (41.5)                       | 55 (58.5)                     |             |
| IV                    | 265                              | 112 (42.3)                      | 153 (57.7)                    |             |
| CTCA hospital         |                                  |                                 |                               | 0.04*       |
| Philadelphia, PA      | 50                               | 13 (26)                         | 37 (74)                       |             |
| Zion, IL              | 269                              | 119 (44.2)                      | 150 (55.8)                    |             |
| Tulsa, OK             | 40                               | 19 (47.5)                       | 21 (52.5)                     |             |
| Histologic subtype\(^a\) |                                  |                                 |                               | 0.90        |
| Adenocarcinoma        | 268                              | 114 (42.5)                      | 154 (57.5)                    |             |
| Squamous cell         | 67                               | 28 (41.8)                       | 39 (58.2)                     |             |
| Others                | 19                               | 9 (47.4)                        | 10 (52.6)                     |             |
| SGA\(^a\)            |                                  |                                 |                               | 0.07        |
| Well-nourished        | 211                              | 81 (38.4)                       | 130 (61.6)                    |             |
| Moderately-severely malnourished | 124 | 60 (48.4) | 64 (51.6) |             |
| ECOG score\(^a\)     |                                  |                                 |                               | 0.02*       |
| 0–1                   | 233                              | 88 (37.8)                       | 145 (62.2)                    |             |
| 2–4                   | 102                              | 52 (51)                         | 50 (49)                       |             |
| Season of diagnosis   |                                  |                                 |                               | 0.004*      |
| Summer                | 93                               | 34 (36.6)                       | 59 (63.4)                     |             |
| Fall                  | 90                               | 27 (30)                         | 63 (70)                       |             |
| Winter                | 72                               | 34 (47.2)                       | 38 (52.8)                     |             |
| Spring                | 104                              | 56 (53.8)                       | 48 (46.2)                     |             |
| Smoking Status\(^a\) |                                  |                                 |                               | 0.006*      |
| Never                 | 69                               | 27 (39.1)                       | 42 (60.9)                     |             |
| Former                | 143                              | 49 (34.3)                       | 94 (65.7)                     |             |
| Current               | 143                              | 75 (52.4)                       | 68 (47.6)                     |             |
| Vitamin D supplementation at diagnosis |         |                                 |                               | 0.92        |
| Yes                   | 163                              | 69 (42.3)                       | 94 (57.7)                     |             |
| No                    | 196                              | 82 (41.8)                       | 114 (58.2)                    |             |

| Continuous variables | Overall population \((n = 359)\) | Deficient: \(<20 \text{ ng/ml} (n = 151)\) | Not deficient: \(\geq 20 \text{ ng/ml} (n = 208)\) | \(P\)-value |
|----------------------|----------------------------------|---------------------------------|-------------------------------|-------------|
| Mean (SD) age (years) | 57.4 (8.4)                       | 57.1 (7.4)                      | 57.6 (9.0)                    | 0.62        |
| Mean (SD) vitamin D (ng/ml) | 25.5 (15.3) | 13.3 (4.1) | 34.4 (14.3) | <0.001* |
| Mean (SD) BMI (kg/m\(^2\)) | 25.8 (5.7) | 25.5 (5.9) | 26 (5.7) | 0.43 |
| Mean (SD) serum albumin (g/dl) | 3.6 (0.57) | 3.5 (0.57) | 3.6 (0.57) | 0.06 |

(SGA Subjective Global Assessment, ECOG Eastern Cooperative Oncology Group, CTCA Cancer Treatment Centers of America, PA Pennsylvania, IL Illinois, OK Oklahoma, BMI Body Mass Index, g/dl grams per deciliter, ng/ml nanograms per milliliter, kg/m\(^2\) kilograms per meter squared, SD Standard Deviation)

\(^a\)Missing data (Histology = 5; SGA = 24; ECOG = 24; Smoking status = 4)
greater proportion of well-nourished patients compared to the Tulsa cohort (45 %); \( p = 0.04 \). Further, the Philadelphia cohort (24 %) had a significantly smaller proportion of current smokers compared to the Zion (42.3 %) and Tulsa (47.5 %) cohorts; \( p = 0.002 \). Finally, the mean baseline serum albumin in the Philadelphia cohort (4.1 grams per deciliter [g/dl]) was significantly higher compared to the Zion (3.4 g/dl) and Tulsa (3.6 g/dl) cohorts; \( p < 0.001 \). There were no systematic differences among the 3 hospitals with regard to age, stage at diagnosis, BMI and ECOG performance status.

The systematic differences among the 3 hospitals with regard to gender, nutritional status, smoking status and serum albumin might, in part, explain the observed differences in median survival.

**Univariate and multivariate survival analysis**

Table 3 summarizes the results of univariate and multivariate Cox regression analyses. In the univariate analysis, each predictor was tested in isolation for its association with survival. Gender, stage of disease, CTCA hospital, histologic subtype, SGA, ECOG performance status, smoking status, BMI and serum albumin were significantly associated with survival. Every 1 kilograms per meter squared (kg/m2) increase in BMI was associated with a 3 % reduction in mortality hazard (HR = 0.97; \( p = 0.008 \)) and every 1 g/dl increase in serum albumin was associated with a 56 % reduction in mortality hazard (HR = 0.44; \( p < 0.001 \)). In the full model, all variables tested in the univariate analysis were evaluated simultaneously in the same model. Six variables demonstrated statistically significant associations with survival: stage of disease, CTCA hospital, histologic subtype, SGA, smoking status and serum albumin. Every 1 g/dl increase in serum albumin was associated with a 54 % reduction in mortality hazard (HR = 0.46; \( p < 0.001 \)). In the final model, only those 6 variables that were statistically significant in the full model were evaluated together. All of them excepting histologic subtype were found to be statistically significant.

To account for potential sampling bias and further investigate the stability of the classical multivariate Cox model reported in Table 3, we conducted a bootstrap resampling procedure based on 1000 samples. We did not find any significant differences in regression coefficients and their corresponding \( p \) values between the classical Cox regression and bootstrap Cox regression models.

**Discussion**

We investigated the association between serum 25(OH)D and survival in newly diagnosed stages III-IV NSCLC patients. The findings of our study add to the growing body of literature on the potential association between serum vitamin D and survival in NSCLC.

Consistent with the findings published by Heist et al. [21], Anic et al. [23] and Turner et al. [22] we did not find a significant association between serum vitamin D and survival in our cohort of newly diagnosed advanced NSCLC patients. The lack of a significant association...
between serum vitamin D and survival in our study could be explained in several ways. First, the disease was far too advanced in our patients for vitamin D levels to have any impact on prognosis. Second, the vitamin D levels in our study were perhaps too low to have any significant impact on the prognosis. Lastly, vitamin D may not have any true impact on survival in advanced NSCLC. Collectively, the results of our study considered against the backdrop of the existing literature in this area suggest that serum vitamin D levels measured either pre- or post-diagnosis might not be independently predictive of survival in advanced NSCLC cancer after controlling for the most Seasons of diagnosis, ECOG performance status, smoking status and hospital location were found to be statistically significantly associated with serum vitamin D levels. Patients diagnosed in the summer and fall months were less likely to be deficient in vitamin D compared to those diagnosed in winter and spring, a finding that has been widely reported in the literature. However, the mean serum vitamin D levels across all 4 seasons were less than 32 ng/ml, a level considered to be sufficient [12, 14]. As a result, consistent with the previous literature [18], the patients in our cohort were not exposed to enough sunlight even during the summer months, and therefore had low circulating 25(OH)D levels. Patients with good performance status were less likely to be deficient in vitamin D compared to those with poor performance status. This finding is not surprising because patients with good performance status can be assumed to be more physically active compared to those with poor performance status. We found that current smokers had a greater prevalence of vitamin D deficiency compared to past or no smokers. By contrast, the study by Anic et al. did not report an association between smoking status and serum vitamin D [23]. There is little information in the literature on the potential biologic mechanisms underlying the relationship between smoking status and serum vitamin D levels. However, given the findings of our study, smoking status is clearly an important covariate to include in all studies evaluating the role of serum vitamin D in predicting mortality in all tobacco-related cancers such as NSCLC. Finally, patients diagnosed at our Philadelphia hospital had a lower prevalence of vitamin D deficiency compared to patients diagnosed at Zion and Tulsa hospitals. This could potentially be attributed to referral bias or might reflect geographic variation in serum vitamin D distribution.

Two predictors demonstrated borderline significance in their association with serum vitamin D levels: serum albumin and nutritional status. Patients with vitamin D deficiency had lower serum albumin levels compared to those with non-deficient serum vitamin D levels, and well-nourished patients had a lower prevalence of vitamin D deficiency compared to malnourished patients; both findings consistent with our recently reported research in prostate cancer [17].

In contrast with previously published research [13, 28–30], we did not find lower serum levels of 25(OH)D to be associated with higher BMI. Multiple mechanisms
have been proposed to explain the association of obesity with hypovitaminosis D, including lack of sunlight exposure from physical inactivity [31] and sequestration of vitamin D in subcutaneous fat depots [32]. As a result, it has been proposed that BMI should be taken into account when assessing a patient’s vitamin D status and more aggressive vitamin D supplementation should be considered in obese cancer patients [30]. This lack of association between serum vitamin D and BMI in our study could be due to a lack of significant variability in BMI levels given our patients’ advanced disease status.

### Table 3 Univariate and multivariate Cox regression analyses of the relationship between serum vitamin D and survival

| Variables                        | Univariate model HR (95 % CI) | Full model HR (95 % CI) | Final model HR (95 % CI) |
|----------------------------------|------------------------------|------------------------|-------------------------|
| Serum vitamin D                  |                              |                        |                         |
| >= 20 ng/ml (reference)          |                              |                        |                         |
| <20 ng/ml                        | 1.2 (0.9–1.6)                | 0.99 (0.8–1.3)         |                         |
| Gender                           |                              |                        |                         |
| Female (reference)               |                              |                        |                         |
| Male                             | 1.3 (1.01–1.6)*              | 1.1 (0.9–1.5)          |                         |
| Stage                            |                              |                        |                         |
| III (reference)                  |                              |                        |                         |
| IV                               | 2.3 (1.8–3.1)*               | 2.3 (1.7–3.2)*         | 2.3 (1.7–3.1)*          |
| CTCA hospital                    |                              |                        |                         |
| Philadelphia, PA (reference)     |                              |                        |                         |
| Zion, IL                         | 3.2 (1.8–5.8)*               | 1.9 (0.9–4.1)          | 2.0 (0.9–4.2)           |
| Tulsa, OK                        | 5.8 (3.0–11.2)*              | 4.0 (1.8–8.8)*         | 4.1 (1.9–8.9)*          |
| Histologic subtype               |                              |                        |                         |
| Adenocarcinoma (reference)       |                              |                        |                         |
| Squamous cell                    | 1.1 (0.8–1.4)                | 0.9 (0.6–1.3)          | 0.9 (0.7–1.3)           |
| Others                           | 2.3 (1.4–3.8)*               | 1.8 (1.02–3.2)*        | 1.7 (0.9–2.8)           |
| SGA                              |                              |                        |                         |
| Well-nourished (reference)       |                              |                        |                         |
| Moderately-severely malnourished | 2.0 (1.6–2.6)*               | 1.4 (1.02–1.8)*        | 1.4 (1.1–1.9)*          |
| ECOG score                       |                              |                        |                         |
| 0–1 (reference)                  |                              |                        |                         |
| 2–4                              | 1.6 (1.2–2.1)*               | 1.2 (0.9–1.6)          |                         |
| Season of diagnosis              |                              |                        |                         |
| Summer (reference)               |                              |                        |                         |
| Fall                             | 1.0 (0.7–1.4)                | 1.4 (0.9–1.9)          |                         |
| Winter                           | 1.2 (0.9–1.7)                | 1.3 (0.9–1.8)          |                         |
| Spring                           | 1.1 (0.8–1.5)                | 1.1 (0.8–1.6)          |                         |
| Smoking status                   |                              |                        |                         |
| Never (reference)                |                              |                        |                         |
| Former                           | 1.5 (1.1–2.1)*               | 1.4 (1.01–2.1)*        | 1.5 (1.1–2.2)*          |
| Current                          | 1.6 (1.1–2.1)*               | 1.3 (0.9–1.9)          | 1.4 (0.9–1.9)           |
| Age (continuous)                 | 1.0 (0.99–1.01)              | 1.01 (0.99–1.02)       |                         |
| Serum vitamin D (continuous)     | 1.0 (0.99–1.01)              |                         |                         |
| BMI (continuous)                 | 0.97 (0.95–0.99)*            | 0.99 (0.97–1.02)       |                         |
| Serum albumin (continuous)       | 0.44 (0.35–0.54)*            | 0.46 (0.34–0.61)*      | 0.46 (0.35–0.61)*       |

(SGA Subjective Global Assessment, ECOG Eastern Cooperative Oncology Group, CTCA Cancer Treatment Centers of America, PA Pennsylvania, IL Illinois, OK Oklahoma, BMI Body Mass Index, ng/ml nanograms per milliliter, HR Hazard Ratio, CI Confidence Interval)

*P < 0.05
In vitro and animal studies have shown that vitamin D has antiproliferative, antimetastasis, and antiangiogenesis activities in lung cancer and may modulate the immune function of lung epithelial cells [18, 33–35]. In human squamous cell carcinoma and lung cancer cell lines and mouse models, 1,25-dihydroxyvitamin D has been shown to inhibit the growth and angiogenesis of tumor cells potentially due to the suppression of response to vascular endothelial growth factor [35]. Also, 1, 25-dihydroxyvitamin D suppresses epidermal growth factor receptor, which signals several tumorigenic processes, such as proliferation and metastasis, in lung cancer [36]. Finally, 1, 25-dihydroxyvitamin D has been hypothesized to stimulate the secretion of protein glues, such as E-cadherin and catenin, making cells more adherent to each other thereby preventing metastases [37].

There are some limitations of our study that are worth acknowledging. This is an association study which cannot prove causality. Reverse causality (the effect of cancer on serum vitamin D levels) is always a possibility in observational studies and cannot be ruled out with certainty [38]. Potential confounding by factors such as exercise, sunlight exposure and dietary vitamin D intake cannot be ruled out, although season of diagnosis was used as a proxy for sunlight exposure. In this study, serum 25(OH)D was measured only once at the time of diagnosis which might not be reflective of vitamin D levels during cancer generation or progression. However, previous research has shown the reliability of a single serum vitamin D assessment over a 5-year period [28]. Similarly, smoking status was only available at baseline based on the information provided by patients. The treatments received were not standardized as they would have been in a clinical trial setting. No formal sample size calculation was conducted before undertaking this study. Finally, the available survival data could not distinguish between death from NSCLC and from other causes; therefore, we assessed the all-cause mortality instead of NSCLC-specific mortality.

There are some strengths of our study. We examined a homogeneous patient population of newly diagnosed advanced NSCLC which minimizes potential confounding by tumor stage and prior treatment history. We measured serum vitamin D at disease diagnosis prior to receiving any treatment which eliminates the possibility of treatment and lifestyle changes affecting serum vitamin D levels after diagnosis. We had a large sample size of histologically confirmed NSCLC cases. By using a consecutive case series of all eligible patients seen at our institution during a fixed time period, we minimized the possibility of selection bias in our study. Lastly, we adjusted for a wide range of potential clinical and demographic confounders thereby minimizing the possibility of residual confounding. That being said, the possibility of residual confounding can never be completely ruled out in observational studies.

Conclusion
In conclusion, we did not find any significant association between serum 25(OH)D and survival in newly diagnosed stages III-IV NSCLC patients. This finding needs further exploration in future prospective studies of larger sample sizes across all stages of NSCLC.

Abbreviations
25(OH)D: 25-hydroxyvitamin D; NSCLC: non-small-cell lung cancer; SGA: subjective global assessment; 1,25(OH)2D: 1,25-dihydroxyvitamin D; CTCA: Cancer Treatment Centers of America; IRB: Institutional Review Board; CLIA: chemiluminescence immune assay; RIA: radioimmunoassay; BMI: body mass index; HRs: hazard ratios; CIs: confidence intervals; PH: proportional hazards; BCa: bias-corrected and accelerated; ECOG: Eastern Cooperative Oncology Group; ng/ml: nanograms per milliliter; SD: standard deviation; g/dl grams per deciliter; IBM: International Business Machines; SPSS: statistical package for social sciences; kg/m2: kilograms per meter squared.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
PG participated in concept, design, data interpretation, writing and general oversight of the study. PE and BP participated in data collection, data interpretation and writing. DG participated in data analysis, data interpretation and writing. All authors read and approved the final manuscript.

Acknowledgements
We would like to thank Diane Ottersen, Shelly Ware and Jane Fridman for providing us with the updated demographic and survival data. This study was funded by Cancer Treatment Centers of America®.

Received: 13 April 2015 Accepted: 21 December 2015 Published online: 24 December 2015

References
1. Bikle D. Nonclassic actions of vitamin D. J Clin Endocrinol Metab. 2009;94:26–34.
2. Gupta D, Vashi PG, Trukova K, Lis CG, Lammersfeld CA. Prevalence of serum vitamin D deficiency and insufficiency in cancer: review of the epidemiological literature. Exp Ther Med. 2011;2:81–93.
3. Adams JS, Hewison M. Update in vitamin D. J Clin Endocrinol Metab. 2010;95:471–8.
4. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266–81.
5. Holick MF. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol. 2009;19:73–8.
6. Ren C, Qiu MZ, Wang DS, Luo HY, Zhang DS, Wang QZ, et al. Prognostic effects of 25-hydroxyvitamin D levels in gastric cancer. J Transl Med. 2012;10:16.
7. Fedirko V, Riboli E, Tjonneland A, Ferrari P, Olsen A, Bueno-de-Mesquita HB, et al. Prediagnostic 25-hydroxyvitamin D, VDR and CASR polymorphisms, and survival in patients with colorectal cancer in western European populations. Cancer Epidemiol Biomarkers Prev. 2012;21:582–93.
8. Fiscella K, Winters P, Tancredi D, Hendren S, Franks P. Racial disparity in death from colorectal cancer: does vitamin D deficiency contribute? Cancer. 2011;117:1061–9.
9. Metzawa H, Sugiuara T, Watanabe M, Nozoe C, Takahashi D, Shimozuma A, et al. Serum vitamin D levels and survival of patients with colorectal cancer: post-hoc analysis of a prospective cohort study. BMC Cancer. 2010;10:347.
10. Moan J, Porojnicu AC, Robashm TE, Dahlback A, Juveniene A, Trelit S, et al. Solar radiation, vitamin D and survival rate of colon cancer in Norway. J Photochem Photobiol B. 2005;78:189–93.
11. Ng K, Meyerhardt JA, Wu K, Feskanich D, Hollis BW, Giovannucci EL, et al. Circulating 25-hydroxyvitamin D levels and survival in patients with colorectal cancer. J Clin Oncol. 2008;26:2984–91.
12. Goodwin PJ, Ennis M, Pritchard NJ, Koo J, Hood N. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol. 2009;27:3757–63.
13. Vrieling A, Hein R, Abbas S, Schneeweis A, Flesch-Janss D, Chang-Claude J. Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study. Breast Cancer Res. 2011;13:R74.
14. Tretli S, Hennes E, Berg JP, Hestvik UE, Roobsham TE. Association between serum 25(OH)D and death from prostate cancer. Br J Cancer. 2009;100:450–4.
15. Fang F, Kasperczyk JL, Shui I, Hendrickson W, Hollis BW, Fall K, et al. Prediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer. PLoS One. 2011;6:e18625.
16. Holt SK, Kolb S, Fu R, Horst R, Feng Z, Stanford JL. Circulating levels of 25-hydroxyvitamin D and prostate cancer prognosis. Cancer Epidemiol. 2013;37:666–70.
17. Gupta D, Trukova K, Popiel B, Lammersfeld C, Vashi PG. The Association between Pre-treatment Serum 25-hydroxyvitamin D and Survival in Newly Diagnosed Stage IV Prostate Cancer. PLoS One 2015;10(3);e0119690.
18. Zhou W, Heist RS, Liu G, Asomanging K, Neuberg DS, Hollis BW, et al. Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. J Clin Oncol. 2002;20:5479–85.
19. Tretli S, Schwartz GG, Torjesen PA, Roobsham TE. Serum levels of 25-hydroxyvitamin D and survival in Norwegian patients with cancer of breast, colon, lung, and lymphoma: a population-based study. Cancer Causes Control. 2012;23:363–70.
20. Cheng TY, Neuhauser ML. Serum 25-hydroxyvitamin D, vitamin A, and lung cancer mortality in the US population: a potential nutrient-nutrient interaction. Cancer Causes Control. 2012;23:1557–65.
21. Heist RS, Zhou W, Wang Z, Liu G, Neuberg D, Su L, et al. Circulating 25-hydroxyvitamin D, VDR polymorphisms, and survival in advanced non-small cell lung cancer. J Clin Oncol. 2008;26:5596–602.
22. Turner AM, McGowan L, Millen A, Rajesh P, Webster C, Langman G, et al. Circulating DBP level and prognosis in operated lung cancer: an exploration of pathophysiology. Eur Respir J. 2013;41:410–6.
23. Anic GM, Weinstein SJ, Mondul AM, Mannisto S, Albanes D. Serum vitamin D, vitamin D binding protein, and lung cancer survival. Lung Cancer. 2014;86:297–303.
24. Liu Y, Chen W, Hu ZX, Xu L, Shu YQ, Pan SY, et al. Plasma vitamin D levels and vitamin D receptor polymorphisms are associated with survival of non-small cell lung cancer. Chin J Cancer Res. 2011;23:33–7.
25. Ensfeld DL, Rao DS, Body JJ, Sackrison Jr JL, Miller AB, Parkih N, et al. Analytical and clinical validation of the 25 OH vitamin D assay for the LIASON automated analyzer. Clin Biochem. 2004;37:867–74.
26. Woolton AM. Improving the measurement of 25-hydroxyvitamin D. Clin Biochem Rev. 2005;26:33.
27. Sauerbrei W, Schumacher M. A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med. 1992;11:2093–109.
28. Hofmann NJ, Yu K, Horst RL, Hayes RB, Purdie MP. Long-term variation in serum 25-hydroxyvitamin D concentration among participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev. 2010;19:27–31.
29. Lagunova Z, Porojnicu AC, Grant WB, Bruland O, Moan JE. Obesity and increased risk of cancer: does decrease of serum 25-hydroxyvitamin D level with increasing body mass index explain some of the association? Mol Nutr Food Res. 2010;54:1127–33.
30. Vashi PG, Lammersfeld CA, Braun DP, Gupta D. Serum 25-hydroxyvitamin D is inversely associated with body mass index in cancer. Nutr J. 2011;10:51. doi:10.1186/1475-2891-10-51.51.
31. Florez H, Martinez R, Chacra W, Strickman-Stein N, Levis S. Outdoor exercise reduces the risk of hypovitaminosis D in the obese. J Steroid Biochem Mol Biol. 2007;103:3679–81.
32. Lee P, Greenfield JR, Seibel MJ, Eisman JA, Center JR. Adequacy of vitamin D replacement in severe deficiency is dependent on body mass index. Am J Med. 2009;122:1056–60.
33. Nakagawa K, Kawaura A, Kato S, Takeda E, Okano T. 1 alpha,25-Dihydroxyvitamin D(3) is a preventive factor in the metastasis of lung cancer. Carcinogenesis. 2005;26:429–40.
34. Pełczyńska M, Wietrzyk J, Jaroszewicz I, Nevozhay D, Switalska M, Kutner A, et al. Correlation between VDR expression and antiproliferative activity of vitamin D3 compounds in combination with cytostatics. Anticancer Res. 2005;25:2235–40.
35. Nakagawa K, Sasaki Y, Kato S, Kubodera N, Okano T. 22-Oxa-1alpha,25-dihydroxyvitamin D3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis. 2005;26:1044–54.
36. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359:1367–80.
37. Zhou W, Suk R, Liu G, Park S, Neuberg DS, Wain JC, et al. Vitamin D is associated with improved survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev. 2005;14:2303–9.
38. Roobsham TE, Schwartz GG, Tretli S. The inverse relationship between 25-hydroxyvitamin D and cancer survival: discussion of causation. Cancers (Basel). 2013;5:1439–55.